AMAG Pharmaceuticals, Inc. is an American pharmaceutical company developing products that treat iron deficiency anemia (IDA) in adult patients. The company was a publicly traded company listed on NASDAQ under the symbol "AMAG" until November 2020 when it was acquired by Covis Pharma.[1]
In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).[2]
Operations
AMAG Pharmaceuticals Inc. operates in the researching, marketing as well as distribution of its drugs. The areas that the company markets its products include the United States, Canada and the European Union.[3]
AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of $71.5 million in 2013.[4]